A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

Completed · Phase 2

Conditions studied: Metabolic Syndrome X

In brief

Agents that increase HDL-C via reverse cholesterol transport could provide a new therapeutic option for the prevention of atherosclerotic cardiovascular disease. The investigators propose to investigate the effects of LY518674 on components that may likely affect atherogenesis in patients with the metabolic syndrome including HDL-C metabolism and reverse cholesterol transport pathways, the inflammatory response, and oxidative stress in human subjects. As an agonist of the nuclear peroxisome proliferator activated receptor (PPAR) alpha, LY518674 may affect the transcription of genes that encode various proteins involved in atherogenesis. This study will explore the consequences of altered transcription such as changes in messenger ribonucleic acid (mRNA) and protein levels as well as protein activity.

Key facts

Study ID

NCT00327002

Run by

University of Pennsylvania

People needed

40

Starts

2006-01-01

Expected to finish

2006-11-01

Last updated by the study team

2015-12-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women between the ages of > = 18 and < = 80.
• HDL-C < 40 mg/dL in men; HDL-C < 50 mg/dL in women.
• At least two of the following criteria ([a], [b], [c], or [d]) listed below:
• Abdominal obesity defined by waist circumference: non-Asian men > = 40 inches (102 cm) and non-Asian women > = 35 inches (88 cm); Asian men > = 35 inches (88 cm) and Asian women > = 31 inches (79 cm),
• Blood pressure > = 130 systolic, or > = 85 diastolic mm Hg (on average of 3 measurements) in untreated patients OR if patient is taking > = 1 approved anti-hypertensive agent,
• Fasting glucose > = 100 mg/dL and < 126 mg/dL,
• Fasting triglycerides > 150 mg/dL and < 600 mg/dL.
• Have given signed informed consent to participate in the study.
• Women of child-bearing potential, that is, women not surgically sterilized and between menarche and 1 year post menopause, must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control (for example, use of oral contraceptives or Norplant®; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices]; partner with vasectomy; or abstinence) during the study and for one month following the last dose of study drug.
• Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

You may not qualify if…

• Potential study subjects may not be entered into the study if any of the following apply:
• Lipid-altering medications that meet any of the following criteria prior to the screening visit, are planned or are likely to be required during the course of the study:
• Subjects who have not been on a stable dose of statin therapy within 4 weeks.
• Subjects who have received fish oil dietary supplements > 2 g/d within 4 weeks.
• Use of more than 250 mg per day of niacin within 6 weeks; fibrates within 12 weeks; or thiazolidinediones (TZDs) within 12 weeks.
• Orlistat and bile acid sequestrants are not permitted within 4 weeks.
• Ezetimibe is not permitted within 4 weeks.
• Postmenopausal women who have not been on a stable selective estrogen receptor modulator (SERM) dose within 4 weeks.
• Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
• Lilly employees.
• Within 30 days of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication.
• Have previously completed or withdrawn from this study or any other study investigating LY518674.
• Patients with diabetes or receiving PPARs consisting of gamma, alpha, delta agonists or gamma, alpha, delta antagonists, or partial agonists alone and in any combination.
• Uncontrolled hypertension defined as systolic blood pressure > 180 mm Hg, diastolic blood pressure > 100 mm Hg.
• Have a serum creatinine > = 2 mg/dL, or nephrotic syndrome, end stage renal disease and use renal replacement therapy such as hemodialysis or peritoneal dialysis.
• Liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP] or total bilirubin) > 1.5 x the upper limit of normal (ULN).
• Have hemoglobin < 10.5 gm/dL in women and < 11.5 gm/dL in men.
• Have or have had any clinical manifestations of coronary heart disease (CHD) such as unstable angina, acute coronary syndrome, a myocardial infarction (MI), a coronary revascularization procedure including stent placement, or any other condition for which statin therapy is recommended for secondary prevention of cardiovascular disease as seen in type 1 and 2 diabetes mellitus or genetic forms of hypercholesterolemia (for example, familial hypercholesterolemia).
• History of congestive heart failure (CHF).
• History of a non-skin malignancy within the previous 5 years.
• Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition.
• Surgery in the last 30 days, or have planned or are likely to require major surgery during the course of the study.
• Subject-reported history of human immunodeficiency virus infection.
• Have chronic alcohol or drug abuse.
• Subjects who have an average weekly alcohol intake that exceeds 14 units per week (1 unit = 12 oz of beer; 5 oz of wine; 1.0 oz of distilled spirits).

Where it is running

• John Millar — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.